ADC Therapeutics nimmt an der Jefferies London Healthcare Conference teil
06 nov. 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Schweiz, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass Ameet Mallik, Chief Executive Officer, auf der Jefferies London Healthcare Conference am...
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
06 nov. 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
MacroGenics to Participate in Upcoming Investor Conferences
02 nov. 2023 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
31 oct. 2023 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
24 oct. 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30...
Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies
11 oct. 2023 04h00 HE
|
Oxford BioTherapeutics
Oxford, UK and San Jose, Calif., 11 October 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers
03 oct. 2023 02h00 HE
|
Oxford BioTherapeutics
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 proteinDLL3 was discovered using OBT’s proprietary OGAP® drug discovery platformFast...
MacroGenics to Participate in Upcoming Investor Conferences
31 août 2023 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
ADC Therapeutics veranstaltet am 8. August 2023 eine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2023
01 août 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Schweiz, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass es am Dienstag, den 8. August 2023, um 8:30 Uhr EDT eine Telefonkonferenz und einen...
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
01 août 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m....